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Evolutionary medicine is the application of evolution theory to understanding health and disease. It provides a complementary
scientiﬁc approach to the present mechanistic explanations that dominate medical science, and particularly medical education.
The chronic multifactorial disease of atherosclerosis clearly illustrates the Darwinian paradigm. Recent research, combining the
eﬀects of genes and environment, has provided surprising clues to the pathogenesis of this major public health problem. This
example makes a strong case for recognizing evolution biology as a basic science for medicine.
1.Introduction
“Nothing in Biology Makes Sense Except in the Light of
Evolution” is a 1973 essay by the great evolutionary biologist
Dobzhansky [1]. He writes: “Seen in the light of evolution,
biology is—perhaps—intellectually the most satisfying and
inspiring science. But without this light, it becomes a pile of
sundryfacts,someoftheminterestingorcuriousbutmaking
no meaningful picture as a whole.”
Evolution’s role is also of paramount importance in the
sub-discipline of biology that addresses health and disease in
humans.
The co-evolution of man and pathogenic microorgan-
isms, as well as man’s persistent vulnerability to chronic
diseases should all be viewed in the context of continuing
evolution. These subjects form the core of “evolutionary
medicine,” also known as “Darwinian medicine” [2].
Evolutionary medicine is not a form of “alternative
medicine.” Actually, it is the opposite, complementing
scientiﬁc evidence-based medicine by not only seeking the
immediate causes of disease—the “how”—but also the
longer-term reasons for the existence of these diseases—the
“why.”
While the practice of medicine by itself aims at coun-
teracting natural selection, the following pledge for evo-
lutionary medicine is not paradoxical. Indeed, it is by
improving the knowledge on evolution biology of clinicians,
learning them to see health and disease from an evolutionary
perspective, that more eﬀective treatment and preventive
strategies can be developed.
Atherosclerosis is an example of the contribution of
Darwinian insights into the aetiology of a major chronic
disease. Recent research, combining the eﬀects of genes and
environment, has provided new clues to the cause of this
leading cause of global morbidity and mortality.
2.GeneticFactors
2.1. Alleles of the Apo E Gene. Genetic factors have an
unquestionable role in atherosclerosis [3].
T h ea p oEg e n e[ 4] is located at chromosome 19q13.2.
Among the variants of this gene, the alleles epsilon2,
epsilon3andepsilon4constitutethecommonpolymorphism
found in most populations, the epsilon3 allele being the
most frequent (>0.60) in all populations studied. The
polymorphism however is not neutral but has functional
eﬀects on lipoprotein metabolism, mediated through the
hepatic binding, uptake, and catabolism of chylomicrons,
chylomicron remnants, very low density lipoproteins and
high density lipoproteins. Epidemiological studies have
demonstrated that the primary genetic risk factor predispos-
ing to atherosclerosis is the epsilon4 allele of the apo E gene
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2.2. Population Genetics and Evolution. The apo E epsilon3
allele is the most frequent in all studied human popula-
tions, its frequency being highest (0.85–0.90) among the
populations of the Mediterranean basin. Correspondingly,
the apo E epsilon4 allele has the lowest frequencies (0.05–
0.13) in Mediterranean populations, who were also the
ﬁrst to establish agricultural economy. On the other hand,
the frequency of the epsilon4 allele remains higher in
populations like Pygmies (0.41), Khoi San (0.37), aborigines
of Malaysia (0.24) and Australia (0.26), Papuans (0.37),
some Native Americans (0.28) and Lapps (0.31), where an
economyofforagingstillexistsorfoodsupplyis(orwasuntil
the recent past) scarce and sporadically available [6].
From the evolutionary perspective, these observations
lead to the conclusion that the epsilon4 allele must be the
ancestral allele [7]. As an evolutionary relic from the pre-
agricultural history of Homo sapiens,i ti sn o ta d a p t e dt o
a modern, highly nutrient-rich culture [8]. Through the
process of natural selection, other, better adapted alleles are
replacing the epsilon4 allele, generation after generation.
Still, the allele has at present, 10000 years after the discovery
of agriculture, still a high frequency. The mechanism of
natural selection eliminating the epsilon4 allele after the
introduction of agriculture, is supported by the fact that
in contemporary populations with a longer tradition of
agriculture the allele is less frequent than in populations that
have shifted more recently to agriculture, and even much less
frequent than in “primitive” populations with a hunter-and-
gatherer lifestyle today [9].
3.EnvironmentalFactors
3.1. Multiple Factors. Aside from genetic factors, there are
also environmental—other than dietary—factors to consider
in atherosclerosis.
It is widely known that cigarette smoking constitutes a
major environmental risk factor for atherosclerosis. Gene/
environment interaction has also been demonstrated in this
regard.Indeed,asynergisticeﬀectbetweencigarettesmoking
and carrier state of the apo E epsilon4 allele increases the risk
of atherosclerosis to a large extent [10].
3.2. Role of Chlamydia Pneumoniae. An environmental fac-
tor of recent interest in the pathogenesis of atherosclerosis is
bacterial infection.
First, histopathological studies in humans have shown—
contrasting with what was traditionally assumed—that
triglyceridesandcholesteroldonotsimplyaccumulateonthe
inner surface of the artery, but within the arterial wall itself.
Within atherosclerotic lesions—somewhat surprisingly—
bacteria have been demonstrated, especially Chlamydia
pneumoniae [11]. This is an intracellular pathogen, known
as a leading cause of human respiratory tract infections
worldwide. In order to play a causative role in chronic
disease, C. pneumoniae would need to persist within infected
tissue for extended periods of time, thereby stimulating a
chronic inﬂammatory response. C. pneumoniae has been
shown to disseminate systemically from the lungs through
infected peripheral blood mononuclear cells and to localize
in arteries where it may infect endothelial cells, vascular
smooth muscle cells, monocytes/macrophages and promote
an inﬂammatory atherogenous process [12].
Also using an animal model, C. pneumoniae have been
demonstrated in atherosclerotic lesions but not in normal
arteries [13]. Apo E knockout mice, which spontaneously
develop atherosclerosis, and C57BL/6J mice, which only
develop atherosclerosis on an atherogenic diet, were evalu-
ated. Following intranasal inoculations of apo E knockout
mice, C. pneumoniae were detected in lung, aorta, and spleen
for 20 weeks in 25 to 100% of mice. In the aorta, C.
pneumoniae were detected within the atherosclerotic lesion.
In C57BL/6J mice on a nonatherogenic diet, C. pneumoniae
were detected in the aorta within 2 weeks after intranasal
inoculation. The persistence of C. pneumoniae in atheromas
suggests a tropism of C. pneumoniae to the lesion. These
mouse models should be useful for studying the pathogenic
role of C. pneumoniae in atherosclerosis.
The synergistic eﬀect between the genetic and the
environmental risk factors has also been elucidated [14].
The gene product of the epsilon4 allele of the apo E gene
functions as a receptor protein permitting C. pneumoniae to
penetrate the endothelial cells of the arterial wall. Thus, all
pieces of the puzzle come together and we get close to proof
that C. pneumoniae is causally involved in atherosclerosis
[15].
3.3. Resolving the “Passive Smoker’s Paradox”. When a respi-
ratory infection is viewed as the primary cause of atheroscle-
rosis, the paradox of “passive smoking” [16]i sr e s o l v e d .
Traditionally, the risk of atherosclerosis by passive smoking
is attributed to the direct eﬀect of toxic compounds in
the smoke. Still, the link between second-hand exposure to
smoke and the increased atherosclerosis risk appears to be
quantitatively problematic. Compared with a nonsmoker,
a heavy smoker increases his risk by 100%. Living with a
smoker increases the risk by 30%, although the exposure to
smoke is 100 times smaller in the passive smoker [17]. Thus,
therelativeeﬀectofpassivesmokingseemsoutofproportion
to the small amount of smoke inhaled. This paradox goes up
in smoke if the primary cause of atherosclerosis is infection,
spread by airway transmission. Smoking indeed increases
the susceptibility to respiratory infection and living together
with a smoker increases the risk of acquiring the same
infection.
The insight thata frequentand potentially mortal disease
could be caused by a bacterium opens new doors for
treatment and prevention.
4. Synthesis andConclusion
The consideration of apo E alleles and smoking provides two
illustrations of a comprehensive approach to the causation
of atherosclerosis. Instead of accumulating risk factors, this
approach seeks a uniﬁed theory of causation. Infection as
a primary cause of atherosclerosis provides a conceptuallyInternational Journal of Hypertension 3
cohesive framework for understanding the role of noninfec-
tious environmental risk factors, such as smoking and diet.
The example of atherosclerosis witnesses the progress
made at the intersection of medicine and evolution, of both
humans and pathogenic microorganisms. The involvement
of C. pneumoniae in atherosclerosis has been shown by
seroepidemiological and pathological studies, in vivo and in
vitro studies and in clinical antibiotic treatment trials. This
factor can be identiﬁed, modiﬁed and may be a therapeutic
target.
Prospective interventionist studies on humans to prove
the relation between genetic evolution and an environmental
risk factor are diﬃcult because of ethical and—above all—
practical reasons (long generation time, limited number of
oﬀspring). Therefore, continued basic research on apo E
knockout mice as well as C57BL/6J mice is needed for the
future [18].
The key questions in evolutionary medicine are centred
around which aspects of modern environment and lifestyle
are pathogenic. That is what we ultimately need to know and
it should be clear to all: Medicine Needs Evolution [19].
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